Overview of selected ongoing clinical trials in MPN-BP
| Agent . | NCT . | Phase . | Patient population . |
|---|---|---|---|
| Decitabine + ruxolitinib or fedratinib | NCT04282187 | 2 | MPN-AP and MPN-BP as bridge to allo-HCT |
| Ruxolitinib + enasidenib | NCT04281498 | 2 | IDH2-mutant MPN-AP, MPN-BP, chronic-phase myelofibrosis |
| Fedratinib + ivosidenib or enasidenib | NCT04955938 | 1 | IDH1- or IDH2-mutant MPN with ≥5% blasts |
| Azacitidine + venetoclax | NCT05074355 | 2 | MPN-AP and MPN-BP |
| KRT-232 (MDM2 inhibitor) | NCT04113616 | 1/2 | post-MPN AML |
| ZN-d5 (BCL2 inhibitor) + ZN-c3 (WEE1 inhibitor) | NA | 1/2 | AML including post-MPN AML |
| Agent . | NCT . | Phase . | Patient population . |
|---|---|---|---|
| Decitabine + ruxolitinib or fedratinib | NCT04282187 | 2 | MPN-AP and MPN-BP as bridge to allo-HCT |
| Ruxolitinib + enasidenib | NCT04281498 | 2 | IDH2-mutant MPN-AP, MPN-BP, chronic-phase myelofibrosis |
| Fedratinib + ivosidenib or enasidenib | NCT04955938 | 1 | IDH1- or IDH2-mutant MPN with ≥5% blasts |
| Azacitidine + venetoclax | NCT05074355 | 2 | MPN-AP and MPN-BP |
| KRT-232 (MDM2 inhibitor) | NCT04113616 | 1/2 | post-MPN AML |
| ZN-d5 (BCL2 inhibitor) + ZN-c3 (WEE1 inhibitor) | NA | 1/2 | AML including post-MPN AML |
NA, not available.